Logo - springer
Slogan - springer

Biomedical Sciences - Cancer Research | Tumors of the Central Nervous System, Volume 2 - Gliomas: Glioblastoma (Part 2)

Tumors of the Central Nervous System, Volume 2

Gliomas: Glioblastoma (Part 2)

Hayat, M.A. (Ed.)

2011, XXII, 458 p.

Available Formats:
eBook
Information

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.

 
$109.00

(net) price for USA
valid until March 31, 2015

ISBN 978-94-007-0618-7

digitally watermarked, no DRM

Included Format: PDF and EPUB

download immediately after purchase


learn more about Springer eBooks

add to marked items

$219.00
Hardcover
Information

Hardcover version

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$139.00

(net) price for USA
valid until March 31, 2015

ISBN 978-94-007-0617-0

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

$279.00
Softcover
Information

Softcover (also known as softback) version.

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$139.00

(net) price for USA
valid until March 31, 2015

ISBN 978-94-007-3580-4

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

$279.00
  • Emphasizes targeted therapy determined by molecular genetics
  • Details several imaging techniques for diagnosis and treatment assessment
  • Describes both current and future therapeutic drugs against malignant gliomas
  • Explains the anti-tumor action of cyclosporine A and functionally-related drugs
  • Covers the topics of brain tumor angiogenesis and glioma grading
Advantages and limitations of biomarkers in gliomagenesis are described. Molecular subtypes of gliomas are detailed. The role played by TP53 gene mutation in the deadliest brain tumor, glioblastoma multiforme, is pointed out. The role of mutations of IDH1 and IDH2, and isocitrate dehydrogenases in malignant gliomas are presented. Metabolic differences in different regions of the glioma tumor are clarified. Various types of imaging modalities, including PET and SPECT, to diagnose gliomas in general and glioblastoma in particular in patients are explained in detail. Both low-grade and high-grade gliomas are discussed. Conventional as well as fluorescent-guided resection techniques for high-grade, recurrent malignant gliomas are detailed. Impact of resection extent on outcomes in patients with high-grade gliomas is clarified. The advantage of the use of intraoperative low-field MRI in glioma surgery is explained.

Content Level » Professional/practitioner

Keywords » Chemotherapy - Diagnosis of brain tumors - Glioblastoma multiforme - Radiotherapy - Treatment of brain tumors

Related subjects » Cancer Research - Oncology & Hematology - Pathology - Radiology - Surgery

Table of contents 

Chapter 1. INTRODUCTION. I. BIOMARKERS AND DIAGNOSIS. Chapter  2. GLIOMAGENESIS: ADVANTAGES AND LIMITATIONS OF BIOMARKERS. Chapter  3. MOLECULAR SUBTYPES OF GLIOMAS. Chapter  4. GLIOBLASTOMA: GERMLINE MUTATION OF TP53. Chapter  5. GLIOMAS: ROLE OF THE TP53 GENE. Chapter  6. THE ROLE OF IDH1 AND IDH2 MUTATIONS IN MALIGNANT GLIOMAS. Chapter  7. MALIGNANT GLIOMA: ISOCITRATE DEHYDROGENASES 1 AND 2  MUTATIONS. Chapter  8. METABOLIC DIFFERNCES IN DIFFERENT REGIONS OF GLIOMA SAMPLES. Chapter  9. GLIOBLASTOMA PATIENTS: ROLE OF METHYLATED MGMT. Chapter  10. BRAIN TUMOR ANGIOGENESIS AND GLIOMA GRADING: ROLE OF TUMOR BLOOD VOLUME AND PERMEABILITY ESTIMATES USING PERFUSION CT. Chapter 11.  VASCULOGENIC MIMICRY IN GLIOMA. Chapter 12. NEWLY DIAGNOSED GLIOMA: DIAGNOSIS USING POSITRON EMISSION TOMOGRAPHY WITH METHIONINE AND FLUOROTHYMIDINE. Chapter  13. ROLE OF DIFFUSION TENSOR IMAGING IN DIFFERENTIATION OF GLIOBLASTOMAS FROM  SOLITARY BRAIN METASTASES. Chapter  14. I-TM-601 SPECT IMAGING OF HUMAN GLIOMA. Chapter  15. ASSESSMENT OF BIOLOGICAL TARGET VOLUME USING POSITRON EMISSION TOMOGRAPHY IN HIGH-GRADE GLIOMA PATIENTS. Chapter  16. SKIN METASTASES OF GLIOBLASTOMA. II. THERAPY. Chapter 17. DIFFUSE LOW-GRADE GLIOMAS. WHAT DOES “COMPLETE RESECTION” MEAN? Chapter 18. QUANTITATIVE APPROACH OF THE NATURAL COURSE OF DIFFUSE LOW-GRADE GLIOMAS. Chapter  19. IMPACT OF RESECTION EXTENT ON OUTCOMES IN PATIENTS WITH HIGH-GRADE GLIOMAS. Chapter 20. RECURRENT MALIGNANT GLIOMAS: 5-AMINOLEVULINIC ACID FLUORESCENCE-GUIDED RESECTION. Chapter 21. GLIOMA SURGERY: INTRAOPERATIVE LOW FIELD MAGNETIC RESONANCE IMAGING. Chapter  22. LOW-GRADE GLIOMAS: INTRAOPERATIVE ELECTRICAL STIMULATIONS. Chapter  23. MALIGNANT GLIOMAS: PRESENT AND FUTURE THERAPEUTIC DRUGS. Chapter 24. RECURRENT MALIGNANT GLIOMA PATIENTS: TREATMENT WITH CONFORMAL RADIOTHERAPY AND SYSTEMIC THERAPY. Chapter  25. GLIOBLASTOMA: BORON NEUTRON CAPTURE THERAPY. Chapter  26. GLIOBLASTOMA: ANTI-TUMOR ACTION OF CYCLOSPORINE A AND FUCTIONALLY RELATED DRUGS.Chapter 27. GLIOBLASTOMA PATIENTS: CHEMOTHERAPY WITH CISPLATIN, TEMOZOLOMIDE AND THALIDOMIDE. Chapter  28. GLIOBLASTOMA : ROLE OF GALECTIN- 1 IN CHEMORESISTANCE. Chapter  29. GLIOMA-INITIATING CELLS: INTERFERON TREATMENT. Chapter  30. GLIOBLASTOMA : ANTITUMOR ACTION OF NATURAL AND SYNTHETIC  CANNABINOIDS. Chapter  31. PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA: THERAPY WITH COMBINATION OF BEVACIZUMAB AND IRINOTECAN. Chapter 32. MONITORING GLIOMAS IN VIVO USING DIFFUSION- WEIGHTED MRI DURING GENE THREAPY –INDUCED APOPTOSIS. Chapter 33. HIGH-GRADE GLIOMAS: DENDRITIC CELL THERAPY. Chapter 34. GLIOBLASTOMA MULTIFORME: USE OF ADENOVIRAL VECTORS. Chapter 35. FISCHER-F98 GLIOMA MODEL: METHODOLOGY. Chapter  36. CELLULAR CHARACTERIZATION OF ANTI-VEGF AND IL-6 THERAPY IN EXPERIMENTAL  GLIOMA. Chapter  37. ADULT BRAINSTEM GLIOMAS: DIAGNOSIS AND TREATMENT . Chapter  38. USE OF LOW MOLECULAR WEIGHT HEPARIN IN THE TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASE IN GLIOMA PATIENTS. III. PROGNOSIS. Chapter 39. BRAINSTEM GLIOMAS: AN OVERVIEW. Chapter  40. TUMOR-ASSOCIATED EPILEPSY IN PATIENTS WITH GLIOMA. Chapter 41. CHRONIC EPILEPSY ASSOCIATED WITH BRAIN TUMORS: SURGICAL NEUROPATHOLOGY. Chapter 42. LOW-GRADE GLIOMAS: ROLE OF RELATIVE CEREBRAL BLOOD VOLUME IN MALIGNANT TRANSFORMATION. Chapter 43. ANGIOCENTRIC GLIOMA- INDUCED SEIZURES: LESIONECTOMY.

Popular Content within this publication 

 

Articles

Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Cancer Research.